CHM CDH17 pre clinical data is stunning. See below. So good in fact that it featured on the cover of NATURE CANCER magazine.....
CHMs target market for GI / CRC and NET cancers is much, much larger than IMU and ALA's lead therapies. ALA and IMU's lead therapies are targeting CD19 related blood cancers, which is an extremely competitive area and only accounts for 10% of the global cancer market, as compared to solid tumours (90% of the market).
CHM has a number of autologous therapies targeting leukemias and lymphomas (and potentially solid tumours) that are currently in 2 x PH1b trials.
Add to My Watchlist
What is My Watchlist?
